Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $7.50 Average Target Price from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $7.50.

Several analysts recently weighed in on the stock. Roth Capital reissued a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Weiss Ratings lowered Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. BTIG Research reaffirmed a “buy” rating and set a $5.00 target price on shares of Gain Therapeutics in a report on Tuesday, August 11th. Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, June 21st. Finally, Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th.

Institutional Trading of Gain Therapeutics

Several institutional investors have recently added to or reduced their stakes in GANX. BlackRock Inc. acquired a new stake in Gain Therapeutics during the 2nd quarter valued at approximately $558,000. GSA Capital Partners LLP bought a new position in Gain Therapeutics during the 2nd quarter worth approximately $1,283,000. Apollon Wealth Management LLC lifted its position in shares of Gain Therapeutics by 33.7% in the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares during the period. Millennium Management LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $45,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at $47,000. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Trading Down 3.8%

GANX opened at $2.04 on Friday. Gain Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $4.34. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. The firm has a market capitalization of $89.03 million, a price-to-earnings ratio of -4.08 and a beta of 0.19. The company’s 50 day moving average price is $1.81 and its two-hundred day moving average price is $1.93.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. As a group, research analysts predict that Gain Therapeutics will post -0.52 earnings per share for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.